Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin's Lymphoma

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 9, 2006, Pages 965-972

  Aksentijevich, Ivan ^a   Jones, Richard J ^a   Ambinder, Richard F ^a   Garrett Mayer, Elizabeth ^a   Flinn, Ian W ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

allogeneic; autologous; BMT; diffuse large cell lymphoma; Lymphoma

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; GAMMA INTERFERON;

ADULT; ADVANCED CANCER; AGE; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PREDICTION; PROBABILITY; T CELL DEPLETION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; BONE MARROW TRANSPLANTATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33747372635     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.05.018     Document Type: Article

References (29)

1. Bellesi G., Rigacci L., Longo G., et al. Treatment of large cell lymphoma with the Fi2 regimen (doxorubicin, vincristine, cyclophosphamide, bleomycin and prednisone). 25-year experience. Oncol Rep 7 (2000) 891-896
2. Zinzani P.L., Martelli M., Magagnoli M., et al. How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?. Haematologica 84 (1999) 996-1001
3. Fisher R.I., Gaynor E.R., Dahlberg S., et al. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermed. Ann Oncol 5 Suppl 2 (1994) 91-95
4. Fisher R.I. Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 40 Suppl (1997) S42-S46
5. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333 (1995) 1540-1545
6. Vose J.M., Zhang M.J., Rowlings P.A., et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission. a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 19 (2001) 406-413
7. Takvorian T., Canellos G.P., Ritz J., et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med 316 (1987) 1499-1505
8. Bolwell B., Goormastic M., and Andresen S. Durability of remission after ABMT for NHL. the importance of the 2-year evaluation point. Bone Marrow Transplant 19 (1997) 443-448
9. Ratanatharathorn V., Uberti J., Karanes C., et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 84 (1994) 1050-1055
10. Rapoport A.P., Lifton R., Constine L.S., et al. Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL). long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 19 (1997) 883-890
11. Verdonck L.F., van Putten W.L., Hagenbeek A., et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332 (1995) 1045-1051
12. Philip T., Armitage J.O., Spitzer G., et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316 (1987) 1493-1498
13. Jones R.J., Ambinder R.F., Piantadosi S., et al. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77 (1991) 649-653
14. Nachbaur D., Oberaigner W., Fritsch E., et al. Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. a single-centre experience. Eur J Haematol 66 (2001) 43-49
15. Chopra R., Goldstone A.H., Pearce R., et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 10 (1992) 1690-1695
16. Schimmer A.D., Jamal S., Messner H., et al. Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada. Bone Marrow Transplant 26 (2000) 859-864
17. Smith S.M., Grinblatt D., and van Besien K. Autologous and allogeneic transplantation for aggressive NHL. Cytotherapy 4 (2002) 223-240
18. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 49 (1982) 2112-2135
19. Wagner J.E., Santos G.W., Noga S.J., et al. Bone marrow graft engineering by counterflow centrifugal elutriation. results of a phase I-II clinical trial. Blood 75 (1990) 1370-1377
20. Noga S.J., Seber A., Davis J.M., et al. CD34 augmentation improves allogeneic T-cell-depleted bone marrow engraftment. J Hematother 7 (1998) 151-157
21. Yeager A.M., Kaizer H., Santos G.W., et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 315 (1986) 141-147
22. Vogelsang G., Bitton R., Piantadosi S., et al. Immune modulation in autologous bone marrow transplantation. cyclosporine and gamma-interferon trial. Bone Marrow Transplant 24 (1999) 637-640
23. Jones R.J., Piantadosi S., Mann R.B., et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 8 (1990) 527-537
24. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
25. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50 (1966) 163-170
26. Cox D.R. Regression models and life-tables. J R Stat Soc 34 (1972) 187-220
27. Conde E., Sierra J., Iriondo A., et al. Prognostic factors in patients who received autologous bone marrow transplantation for non-Hodgkin's lymphoma. Report of 104 patients from the Spanish Cooperative Group GEL/TAMO. Bone Marrow Transplant 14 (1994) 279-286
28. Prince H.M., Imrie K., Crump M., et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma. identification of major prognostic groups. Br J Haematol 92 (1996) 880-889
29. Gulati S., Yahalom J., Acaba L., et al. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. J Clin Oncol 10 (1992) 936-941